dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pozo Rosich, Patricia |
dc.contributor.author | Detke, Holland |
dc.contributor.author | Wang, Shufang |
dc.contributor.author | Doležil, David |
dc.contributor.author | Li, Lily Q. |
dc.contributor.author | Aurora, Sheena K. |
dc.contributor.author | Reuter, Uwe |
dc.date.accessioned | 2022-08-19T06:42:20Z |
dc.date.available | 2022-08-19T06:42:20Z |
dc.date.issued | 2022-04-15 |
dc.identifier.citation | Pozo-Rosich P, Detke HC, Wang S, Doležil D, Li LQ, Aurora SK, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022 Apr 15;38(5):731–42. |
dc.identifier.issn | 1473-4877 |
dc.identifier.uri | https://hdl.handle.net/11351/8019 |
dc.description | Galcanezumab; Migraña crónica; Tratamiento preventivo |
dc.language.iso | eng |
dc.publisher | Taylor & Francis |
dc.relation.ispartofseries | Current Medical Research and Opinion;38(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Migranya - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Migraine Disorders |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1080/03007995.2022.2059975 |
dc.subject.decs | trastornos migrañosos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1080/03007995.2022.2059975 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Detke HC] Eli Lilly and Company, Indianapolis, IN, USA. [Wang S] Eli Lilly and Company, Indianapolis, IN, USA. Now at Sarepta Therapeutics, Cambridge, MA, USA. [Doležil D] Prague Headache Center, DADO MEDICAL s.r.o, Prague, Czech Republic. [Li LQ] Eli Lilly and Company, Indianapolis, IN, USA. [Aurora SK] Eli Lilly and Company, Indianapolis, IN, USA. Now at Impel NeuroPharma, Seattle, WA, USA . [Reuter U] Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany |
dc.identifier.pmid | 35392739 |
dc.identifier.wos | 000782893800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |